This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Santoro, M. G. Articles by Amici, C. Search for Related Content PubMed PubMed Citation Articles by Santoro, M. G. Articles by Amici, C.

Modulation of the Growth of a Human Erythroleukemic Cell Line (K562) by Prostaglandins: Antiproliferative Action of Prostaglandin A¹

Institute of Experimental Medicine, C. N. R., II University of Rome, Via O. Raimondo, 00173 Rome [M. G. S., A. C.], and Center of Virology, Osp. S. Camillo, C. Gianicolense 85, 00152 Rome [A. B., C. A.], Italy

Among several prostaglandins (PGs) tested, PGF₁ was found to slightly enhance, while PGAs and PGDs were found to drastically inhibit the growth of K562 cells in culture. This effect was dose dependent. While PGD₂ was cytotoxic, PGA₁ treatment could totally inhibit K562 cell proliferation, without affecting cell viability. PGA₁ action was reversible; however, K562 cells totally lost their growth potential after prolonged exposure to PGAs.

While it did not significantly affect DNA and RNA synthesis, PGA₁ partially inhibited protein synthesis and glycosylation in these cells. In particular, the production of two polypeptides with molecular weights of 92,000 and 46,000, respectively, was decreased, while the synthesis of a protein with a molecular weight of 74,000 was induced.

These results strongly support the concept that PGs are involved in the regulation of cell proliferation, and that PGs containing a reactive ,ß-unsaturated carbonyl group in the cyclopentane ring are potential antineoplastic agents.

¹ This work was partially supported by a grant from the National Council of Research of Italy, P. F. "Control of Infectious Diseases," No. 8403243.

² To whom requests for reprints should be addressed.

Received 3/13/86. Revised 8/ 1/86. Accepted 8/14/86.